Evofem Biosciences Announces Padagis Will Not Seek FDA Approval To Market A Generic Version Of Phexxi Until Evofem's Phexxi Patents Expire
Portfolio Pulse from Benzinga Newsdesk
Evofem Biosciences announced that Padagis will not seek FDA approval to market a generic version of Phexxi until Evofem's Phexxi patents expire. Evofem has Phexxi patent protection through 2033.
September 27, 2023 | 12:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Evofem Biosciences' Phexxi patents will not be challenged by Padagis, ensuring market exclusivity until 2033.
The decision by Padagis not to seek FDA approval for a generic version of Phexxi until Evofem's patents expire ensures market exclusivity for Evofem. This is likely to have a positive impact on Evofem's stock in the short term as it reduces competition and potential loss of market share.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100